Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SOL-007
- Development stage
- Preclinical
- Lead developer
- Soley Therapeutics
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
SOL-007 is a preclinical-stage, orally administered small molecule therapeutic under development by Soley Therapeutics for the treatment of oncology. The compound was identified and optimized using Soley's proprietary AI-driven discovery platform, which integrates deep learning with biological datasets to target specific cancer pathways. While the exact molecular target of SOL-007 has not been publicly disclosed by the sponsor, the program represents a key asset in Soley's precision medicine pipeline aimed at addressing unmet needs in solid or hematological malignancies.
- Other names
- SOL-007SOL007SOL 007
Beyond the preview
Go deeper on SOL-007.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SOL-007.